New Molecular Entity and New Therapeutic Biological Product Approvals
Drug Name | Active Ingredient | Date | FDA-approved use on approval date |
Daklinza | daclatasvir | 7/24/2015 | To treat chronic hepatitis C virus (HCV) genotype 3 infections |
Odomzo | sonidegib | 7/24/2015 | To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. |
Praluent | alirocumab | 7/24/2015 | To treat certain patients with high cholesterol |